Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ONS

Oncobiologics (ONS) Stock Price, News & Analysis

Oncobiologics logo

About Oncobiologics Stock (NASDAQ:ONS)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$1.31
$1.42
50-Day Range
$0.72
$7.40
52-Week Range
$0.57
$1.53
Volume
284,864 shs
Average Volume
69,024 shs
Market Capitalization
$95.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Remove Ads
Receive ONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

ONS Stock News Headlines

Musk’s real agenda in D.C.
In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…
Are Away Carry-Ons Worth the Hype?
ONS - the Office of National Statistics
See More Headlines

ONS Stock Analysis - Frequently Asked Questions

Oncobiologics (ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR) and Exelixis (EXEL).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ONS
Previous Symbol
NYSE:ONS
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-38,840,000.00
Net Margins
-464.47%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.81 million
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-0.97

Miscellaneous

Free Float
N/A
Market Cap
$95.30 million
Optionable
Not Optionable
Beta
-0.27
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ONS) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners